A Randomized, Controlled Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective (Beta RELIEVED II).

Trial Profile

A Randomized, Controlled Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective (Beta RELIEVED II).

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs Canakinumab (Primary) ; Triamcinolone
  • Indications Gouty arthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Beta-RELIEVED-II
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Nov 2011 Planned end date changed from 1 Aug 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov. [First extension: NCT01080131]
    • 21 Nov 2011 Planned end date changed from 1 Aug 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov. [First extension: NCT01080131]
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top